FREE Daily Stock Alerts From Stock-PR.com
MSLP, MusclePharm Corporation, MSLP.OB
MSLP is one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products.
** Musclepharm sponsered Jake Shields won his UFC debut **
UFC star Jake Shields wore MusclePharm apparel at the UFC 121 co-main event, which took place on October 23 from the Honda Center in Anaheim, California.
Musclepharm sponsered Jake Shields won his UFC debut, but struggled to get it, pulling off a split decision over Martin Kampmann. Shields seemed to be completely gassed by the middle of the second round and struggled to do much in the final seven or eight minutes.
But judges had it 30-27 and 29-28 for Shields and 29-28 for Kampmann, apparently qualifying Shields for a shot at the winner of the welterweight title bout at UFC 124 on Dec. 11 between champion Georges St. Pierre and Josh Koscheck. Yahoo! Sports' Kevin Iole, Dave Doyle and Dave Meltzer all had it 29-28 Kampmann.
Kampmann never let his hands go, and that may have hurt him with the judges.
UFC 121 Matches draw an estimated 850,000 pay per view buys and is watched by an estimated 10 million viewers.
MSLP's products are currently available in 1,200 of the top General Nutrition Centers (GNC) in the United States, as well as Vitamin Shop. MSLP's award-winning products Assault®, Battle Fuel®, Bullet Proof®, Combat Powder®, Recon® and Shred Matrix®are also available online at gnc.com, bodybuilding.com, amazon.com and many other locations.
Furthermore, recently Ron Sekura, B.S., M.S., PhD., will join MusclePharm board of directors as its Director of Therapeutic Research.
Dr. Sekura will be assisting in the development of the Company's therapeutic indication and application for patients with HIV experiencing catabolic cachexia.
Ron Sekura is currently President of VivoNex LLC and Biotechnology Assessment Services, Inc. Dr. Sekura is the former Chief of the Pharmaceutical and Regulatory Affairs Branch of the Division of AIDS at The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institute of Health (NIH), as well as a former Research Chemist at The National Institute of Child Health and Human Development (NICHD) at the NIH and the Center for Biologics Evaluation and Research (CBER). He received his Bachelor of Science and Master of Science in Biochemistry degrees at Pennsylvania State University and his PhD at Cornell University. Dr. Sekura is the author of over sixty scientific publications.
MSLP is presently preparing their application for Recon to be added to the Medicaid formulary, beginning in New York State for people diagnosed with HIV and AIDS as well as nation-wide Veterans Administration therapeutic formularies. In addition, MSLP is exploring the distribution of MusclePharm products, such as Recon, to people living with HIV in developing nations thru The Global Fund to Fight AIDS, Tuberculosis and Malaria, and The Presidents Emergency Plan for AIDS Relief (PEPFAR)
More about MSLP at www.musclepharm.com.
Phoenix Managed Networks, LLC has been awarded a multi-year agreement by Cardtronics, Inc. (NASDAQ:CATM) to provide mission critical financial transaction transport services to Cardtronics and its customers.
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST) recently reported the successful pricing of $400 million aggregate principal amount of its 2.50% Convertible Senior Notes due 2017.
CBST has granted the underwriters an option to purchase up to an additional $50 million aggregate principal amount of the notes.
Pinnacle Financial Partners, Inc. (Nasdaq:PNFP) recently reported its third quarter results.
Net income per fully diluted common share available to common stockholders was $0.02 for the quarter ended Sept. 30, 2010, compared to net loss per fully diluted common share available to common stockholders for the quarter ended Sept. 30, 2009, of $0.15.
PNFP also reported a net loss per fully diluted common share available to common stockholders of $1.00 for the nine months ended Sept. 30, 2010, compared to a net loss per fully diluted common share available to common stockholders of $1.39 for the nine months ended Sept. 30, 2009.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and seventy five thousand free trading shares from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup